Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Walvax Biotech Soars after ChiNext IPO

publication date: Nov 12, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Yunnan Walvax Biotechnology completed its IPO on the Shenzhen ChiNext Exchange, pricing 25 million shares at 95 RMB each ($14.32). The offering raised 2.375 billion RMB ($358 million). In open market trading, investors pushed the shares substantially higher. Walvax opened at 150 RMB and closed at 136.35, a gain of 44% for those who participated in the offering. The rise gives Walvax a market capitalization of 13.6 billion RMB ($2 billion). More details....

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...